Guilford Aggrastat PCI Superiority Trial Planned For 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to meet with FDA shortly to discuss design of a placebo-controlled superiority trial for percutaneous coronary intervention. Aggrastat sales decline beginning to slow; sales could improve in the second half of the year, Guilford says.
You may also be interested in...
Guilford CEO Search Ends With Appointment Of Bristol Exec
Bristol VP-Strategy Dean Mitchell will join Guilford Dec. 1, replacing company co-founder Craig Smith, who is retiring. Mitchell is expected to oversee a busy period for the company, which anticipates results from up to 13 late-stage clinical trials during the next 12-18 months.
Guilford CEO Search Ends With Appointment Of Bristol Exec
Bristol VP-Strategy Dean Mitchell will join Guilford Dec. 1, replacing company co-founder Craig Smith, who is retiring. Mitchell is expected to oversee a busy period for the company, which anticipates results from up to 13 late-stage clinical trials during the next 12-18 months.
Guilford CEO Search Commences As Smith Announces Retirement Plans
Co-founder and CEO Craig Smith, MD, will retire in May 2005 unless a successor is found earlier. The company is looking for an executive with “superb credentials in commercial development, financial planning and late-stage product development” who can lead Guilford to profitability, Smith says.